Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of $0.61, $0.08 better than the analyst estimate of $0.53. Revenue for the quarter came in at $44.05 million versus the consensus estimate of $40.77 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.